Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
Go back to Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (| (NASDAQ: PRTC) | Delayed: 17.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.42 | 52 Week High | $ | |||
| Open | $17.42 | 52 Week Low | $ | |||
| Day High | $17.42 | P/E | N/A | |||
| Day Low | $17.42 | EPS | $ | |||
| Volume | 2,088 | |||||
